EWTX - Edgewise Therapeutics, Inc.
IEX Last Trade
28.89
0.105 0.363%
Share volume: 16,237
Last Updated: Fri 27 Dec 2024 08:30:30 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$28.78
0.11
0.36%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.07%
1 Month
-7.89%
3 Months
13.68%
6 Months
69.49%
1 Year
145.12%
2 Year
247.71%
Key data
Stock price
$28.89
DAY RANGE
$28.44 - $29.85
52 WEEK RANGE
$10.10 - $38.12
52 WEEK CHANGE
$171.12
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Kevin Koch
Region: US
Website: edgewisetx.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: edgewisetx.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Edgewise Therapeutics, Inc. develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy.
Recent news